× The federal government has shut down due to the failures of the President and Congress to continue government funding. Millions of Californians receiving benefits from state programs may be impacted. For now, California’s Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) will continue to provide services and enroll eligible families as long as funding is available. No new federal funding to California WIC will be provided until the President and Congress take action. Families should continue to use their WIC benefits and attend their WIC appointments. This information is subject to change, so please monitor the California WIC website for updates.

Please be wary of potential highly partisan political messaging while visiting federal government websites for information related to the federal government shutdown.

Casirivimab-Imdevimab-Fact-Sheet Casirivimab/Imdevimab (REGEN-COV) Distribution Fact Sheet

Top Menu

Casirivimab/Imdevimab (REGEN-COV) Distribution Fact Sheet

February 2, 2022

Updates as of February 2, 2022:

  • With the predominance of the Omicron variant, National Institutes of Health (NIH) treatment recommendations, and recent data showing that bamlanivimab/etesevimab and casirivimab/imdevimab (REGEN-COV) are not effective against the Omicron variant, the FDA has revised the EUAs for these two monoclonal antibodies. Bamlanivimab/etesevimab and casirivimab/imdevimab (REGEN-COV) are currently not authorized for use in any U.S. states, territories, and jurisdictions. 


With the rapid spread of the Omicron variant in mid-December 2021 and data showing that casirivimab/Imdevimab (REGEN-COV) is not effective in patients infected with this variant, the NIH updated their treatment guidelines to recommend against the use of casirivimab/Imdevimab (REGEN-COV) on January 19, 2022.

On January 24, 2022, the FDA revised the EUA for casirivimab/Imdevimab (REGEN-COV) to limit its use. Casirivimab/Imdevimab (REGEN-COV) is not authorized for use in any U.S. states, territories, and jurisdictions at this time.

HHS has paused allocation of casirivimab/Imdevimab (REGEN-COV), and, at this time, CDPH is not distributing casirivimab/Imdevimab (REGEN-COV) to jursidictions. This product is not available and cannot be ordered.

If future variants are found to be susceptible to casirivimab/Imdevimab (REGEN-COV), this product may become available in the future

 

​Originally published on Decemeber 31, 2020